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Adipose tissue plays a key role as a fat-storage depot and as an endocrine organ. Although mouse
adipogenesis has been studied extensively, limited studies have been conducted to characterize this
process in humans. We carried out a temporal proteomic analysis to interrogate the dynamic changes
in the secretome of primary human preadipocytes as they differentiate into mature adipocytes. Using
iTRAQ-based quantitative proteomics, we identiﬁed and quantiﬁed 420 proteins from the secretome
of differentiated human adipocytes. Our results revealed that the majority of proteins showed differential
expression during the course of differentiation. In addition to adipokines known to be differentially
secreted in the course of adipocyte differentiation, we identiﬁed a number of proteins whose dynamic
expression in this process has not been previously documented. They include collagen triple helix
repeat containing 1, cytokine receptor-like factor 1, glypican-1, hepatoma-derived growth factor, SPARC
related modular calcium binding protein 1, SPOCK 1, and sushi repeat-containing protein. A bioinfor-
matics analysis using Human Protein Reference Database and Human Proteinpedia revealed that of
the 420 proteins identiﬁed, 164 proteins possess signal peptides and 148 proteins are localized to the
extracellular compartment. Additionally, we employed antibody arrays to quantify changes in the levels
of 182 adipokines during human adipogenesis. This is the ﬁrst large-scale quantitative proteomic study
that combines two platforms, mass spectrometry and antibody arrays, to analyze the changes in the
secretome during the course of adipogenesis in humans.
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Introduction
Adipocytes play a central role in the control of energy
balance and lipid homeostasis. As the primary storage depot
for triglycerides (TG), adipose tissue is the most efﬁcient source
of energy reserve in humans as TG is anhydrous and therefore
is stored at a maximum caloric density of ∼9 kcal/g.
1 Obesity,
resulting from both hyperplasia and hypertrophy of adipocytes,
is tightly linked to type 2 diabetes and cardiovascular diseases;
as such, it is a major health risk in the world.
2 Aside from being
a fat-storage depot, adipocytes are also endocrine cells that
actively regulate signaling pathways responsible for energy
balance and lipid homeostasis through the secretion of hor-
mones, cytokines, growth factors and other proteins, col-
lectively termed adipokines.
3 Among the well-studied adipok-
ines are adiponectin, leptin, resistin, plasminogen activated
inhibitor 1 (PAI-1), and proinﬂammatory cytokines IL-6 and
TNF-R. Dysregulation in the circulating levels and actions of
adipokines are causally linked to the pathogenesis of insulin
resistance, diabetes and obesity.
The differentiation of preadipocytes into adipocytes is a
complex process that is tightly regulated and orchestrated by
a network of transcription factors acting in a precisely con-
trolled temporal fashion to coordinate the expression of the
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Published on Web 08/14/2010machinery required to specify a fully functional, mature
adipocyte.
4 The transcription factor, peroxisome proliferator-
activated receptor-gamma (PPAR-gamma), plays a central role
in driving the adipogenic program; ectopic expression of PPAR-
gamma in nonadipogenic mouse ﬁbroblasts is sufﬁcient to
recapitulate much of the adipocyte phenotype.
5 The important
role of PPAR-gamma in adipogenesis is supported by many in
vitro and in vivo studies.
6,7 Major advances in understanding
the molecular underpinning of adipogenesis were made pos-
sible by the establishment of a ﬁbroblast cell line (3T3-L1)
highly capable of differentiating into mature adipocytes ﬁlled
with lipid droplets.
8 This in vitro system has allowed investiga-
tors to employ molecular biology techniques to identify speciﬁc
genes induced during adipocyte differentiation in culture,
allowing the establishment of temporal gene expression pat-
terns that specify sequential events in this process. Although
microarray-based approaches have been extensively and suc-
cessfully used to analyze changes in gene expression during
adipogenesis, only a limited number of studies have been
carried out to evaluate alterations in protein content, due
primarily to the greater technical challenge.
9
Recently, several mass spectrometry-based proteomics stud-
ies have been reported in primary mouse adipose tissue or in
vitro differentiated 3T3-L1 mouse adipocytes.
10-13 These stud-
ies demonstrate that, during differentiation, the entire secretory
proteome (termed the secretome) of 3T3-L1 adipocytes changes
dramatically with the most prominent changes involving the
extracellular matrix components, cytokines, antioxidants, and
complement factors. One mass spectrometry study has also
been carried out on primary rat adipocytes.
14 To date, two
groups have characterized the secretome of differentiated
human adipocytes.
15,16 A major limitation of these studies is
the use of 2-dimensional gels to separate proteins prior to
identiﬁcation by mass spectrometry, thus precluding a greater
depth of analysis. A second limitation relates to the scope; by
restricting the analysis of the secretome to preadipocytes versus
mature adipocytes, the investigators were not able to capture
the dynamic temporal changes in protein expression through-
out the differentiation process. To overcome these limitations,
we have previously described a 5-plex SILAC strategy to
quantify temporal changes of the secretome during mouse 3T3-
L1 adipocyte differentiation in culture;
12 however, a similar
study has not been carried out in humans.
Isobaric tags for relative and absolute quantiﬁcation (iTRAQ)
can be used for multiplexed quantitation of proteins by tandem
mass spectrometry.
17,18 In this study, we employed an iTRAQ-
based strategy to speciﬁcally characterize the secretory pro-
teome and to proﬁle the temporal changes during human
adipogenesis. In addition to identifying many proteins previ-
ously known to be secreted by adipocytes such as adiponectin
and adipsin, we also uncovered proteins not known to be
present in the secretome during adipogenesis. Further, we
employed a high-throughput antibody array method to validate
some of our proteomic data and to proﬁle the secretome for
additional proteins not originally detected by mass spectrom-
etry. Quantitation of the secretome during adipogenesis re-
vealed dynamic expression patterns of these adipokines that
were underappreciated in proteomics studies in humans. Our
study represents the largest proteomic analysis of the primary
human adipocyte secretome carried out to date.
Experimental Procedures
Differentiation of Human Primary Preadipocytes to
Adipocytes. The differentiation of human primary preadipo-
cytes to adipocytes was carried out essentially as previously
described.
19 The Adipocyte Core of The Boston Obesity Nutri-
tion Research Center (BONRC) provided the preadipocytes.
Brieﬂy, subcutaneous fat tissue was obtained from subjects
(females aged 41.6 ( 5.4 years and a BMI of 36 ( 7.6)
undergoing panniculectomy surgery. The fat tissue then un-
derwent collagenase digestion and the preadipocytes were
separated from adipose tissue contaminants such as macroph-
ages and vascular cells by techniques previously described.
20
Then these preadipocytes were grown in preadipocyte media
(DMEM/F12 supplemented with 15 mM HEPES, 15 mM
NaHCO3,2m ML-glutamine, 10% NuSerum, 0.16 mM penicillin
and 0.06 mM streptomycin) for seven days while media were
changed every three days. Five subjects’ samples were pooled
on the basis of having equivalent rates of differentiation based
on lipid content indicated by oil red O staining and the
percentage of cells containing lipid droplets. Cells were seeded
at conﬂuence after cellular proliferation ended so that each
subject was equally represented in the pooled cell population.
Pooled preadipocytes were cultured in differentiating media
(DMEM/F12 supplemented with 15 mM NaHCO3,1 7µM
pantothenate, 10 mg/L transferin, 33 mM biotin, 1 g/L Fetuin,
0.16 mM penicillin and 0.06 mM streptomycin) and induced
by a cocktail inducer (0.5 µM human insulin, 0.1 µM dexam-
ethasone, 2 nM T3, 1 µM ciglitazone and 540 µM IBMX) to
differentiate into adipocytes during a 12-day period while
media was changed every 3 days. After 8 days, the cocktail
inducer was removed and cells were maintained in differentiat-
ing media. Preadipocytes or differentiating adipocytes were
washed extensively with PBS and cultured overnight in serum-
free media for harvesting the conditioned media.
iTRAQ Labeling of Secretome. After normalization by cell
number, the conditioned media were resolved by SDS-PAGE.
Proteins in the gel were stained by a silver staining protocol.
The conditioned media were desalted using Amicon centrifugal
ﬁlters with a 3-kDa cutoff and concentrated. The concentrated
conditioned media were normalized and subjected to iTRAQ
labeling (Applied Biosystems) according to the manufacturer’s
instructions. Brieﬂy, the conditioned media were incubated
with the reducing agent (tris(2-carboxyethyl) phosphine (TCEP))
at 60 °C for 1 h, alkylated with the cysteine blocking reagent,
methyl methanethiosulfonate (MMTS)) for 10 min at room
temperature and digested using sequencing grade trypsin
(Promega) (1:10) for 12 h at 37 °C.
17 The resulting peptides were
labeled with iTRAQ reagents (day 0, 117; day 6, 116; day 9, 115;
and day 12, 114). After iTRAQ labeling, the peptides were mixed
and fractionated by a strong cation exchange (SCX) chroma-
tography on PolySULFOETHYL A column (PolyLC, Columbia,
MD) (100 × 2.1 mm, 5 µm particles with 300 Å pores) using
Agilent HPLC connected to an automated sample collection
system. Forty-three SCX fractions were collected from a 0-350
mM KCl gradient in the presence of 10 mM potassium
phosphate buffer (pH 2.85), containing 25% acetonitrile. The
fractions were dried and analyzed by LC-MS/MS as described
below.
LC-MS/MS and Data Analysis. LC-MS/MS analysis of the
sample was carried out using reversed phase liquid chroma-
tography interfaced with an LTQ-Orbitrap XL ETD mass
spectrometer (Thermo Scientiﬁc). The reversed phase system
consisted of a trap column (3 cm ×75 mm, C18 material 5-10
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material 5 mm, 120 Å). The peptides were separated by
acetronitrile gradient (0-60%) containing 0.1% formic acid. The
MS spectra were acquired in a data-dependent manner target-
ing the nine most abundant ions in each survey scan. The
settings used were: (1) Precursor scans (FTMS) from 350-1600
m/z at 60,000 resolution; (2) PQD fragmentation of the most
intense 9 ions (isolation width, 2.50 m/z; normalized collision
energy, 32.5%; activation Q ) 0.450; activation time ) 0.350
ms). Proteome Discoverer version 1.1 (Thermo Scientiﬁc) was
used for identiﬁcation and quantitation of proteins. The data
were searched against human RefSeq database version 35
containing 39 380 protein entries. The ﬁxed modiﬁcations
included iTRAQ 4plex on N-terminal and lysine residues and
methylthiolation of cysteine residues. The variable modiﬁca-
tions included oxidation of methionine residues and deami-
nation of asparagine or glutamine residues; digestion enzyme,
trypsin; maximum number of missed cleavages, 2; peptide mass
tolerance, 20 ppm; fragment mass tolerance, 0.5 Da. Quanti-
tation was carried out whenever there were one or more iTRAQ
reagent ratios for a peptide.
Relative Quantitation of Adipokines Using an Antibody
Array. Relative quantitation of adipokines in the secretome was
also carried out using an adipokine antibody array (RayBiotech,
Norcross GA) according to the manufacturer’s instructions.
Brieﬂy, the conditioned media normalized by cell number was
dialyzed overnight against PBS at 4 °C and incubated with
biotin-labeling reagents to biotinylate the primary amine of the
proteins in the media. The biotin-labeled samples were added
to the glass chip and incubated at 4 °C overnight. After washing,
the array was incubated with ﬂuorescent dye-conjugated
streptavidin. The signal was visualized by Axon Genescanner
and the data analyzed using GenePix Pro (ver 6.0) as per the
manufacturer’s instructions.
Clustering of Identiﬁed Proteins. We used fuzzy c-means
(FCM) clustering to classify the proteins based on their changes
in abundance during differentiation.
21 FCM clustering gives
each protein a membership value of belonging to a category.
The membership value indicates the quality of the category
assignment for that particular protein. We used the R e1071
package to implement the algorithm. Proteins having missing
abundances were dropped from the analysis. The abundance
ratios instead of the protein concentrations were used so that
the values are on the same scale. The abundance ratios on day
0, day 6 and day 9 were calculated for each protein using the
abundance on day 12 as the baseline. We set the degree of
fuzziﬁcation to 2 (the default value in the implementation) and
explored different number of clusters. We found that 3-cluster
setting gives a reasonably good result. Setting a higher number
of clusters simply split the existing categories into sub categories.
Results and Discussion
Mass Spectrometric Analysis of the Adipocyte Secretome
during Differentiation. Subcutaneous human preadiopocytes
were derived from adipose tissue that was harvested during
panniculectomy surgery. After culturing in differentiation media
for 12 days, the conversion of human preadipocytes to mature
adipocytes was conﬁrmed by visualizing the presence of lipid
droplets using phase-contrast microscopy. Figure 1A shows
preadipocytes (Day 0) and adipocytes at different stages of
differentiation (Days 6, 9 and 12). Proteins in the conditioned
media from the same number of cells at different stages of
differentiation were resolved by SDS-PAGE and visualized by
silver-staining. Figure 1B clearly shows that adipocytes at late
stages of differentiation (Days 9 and 12) secrete more proteins
than preadipocytes (Day 0) or adipocytes at an earlier stage of
differentiation (Day 6). After normalization by cell numbers,
the secretomes during the course of adipocyte differentiation
were compared using an iTRAQ-based quantitative proteomics
approach, as illustrated in Figure 2. After iTRAQ labeling,
peptides derived from different stages of differentiation were
mixed and fractionated into 43 fractions by strong cation
exchange chromatography. Analysis of these fractions by
LC-MS/MS on an LTQ-Orbitrap Fourier transform mass
spectrometer generated 15 807 MS/MS spectra. We identiﬁed
420 proteins using an FDR cutoff of 1% at the peptide level.
Dynamic Changes in Adipocyte Secretome during Adipogen-
esis. iTRAQ-based quantitation of proteins in the secretome
revealed the expression of many secreted proteins during the
course of adipocyte differentiation in humans (Supplementary
Table 1, Supporting Information). Comparison between Day 0
and Day 12 demonstrated that the majority of proteins (94%)
showed an overall trend of increased secretion while 20
proteins (5%) seemed to show a trend of reduced expression
during adipogenesis. However, the expression levels obtained
from iTRAQ-based quantitation revealed that conventional
‘downregulation’ and ‘upregulation’ terms cannot accurately
and adequately describe the temporal expression patterns of
these proteins throughout adipogenesis. The representative
MS/MS spectra of peptides from 4 proteins-adiponectin, lac-
totransferrin, dimethylarginine dimethylaminohydrolase 1, and
cathepsin B - are shown in Figure 3 with each showing a
characteristic proﬁle. Thus, we used a clustering method to
search for patterns in the temporal changes of the secretory
proteome during adipogenesis. From this analysis, we catego-
rized proteins into three major protein expression patterns in
the secretome during adipogenesis. The changes in the expres-
sion levels of representative proteins from each pattern are
shown in Figure 4. We will discuss these patterns and associ-
ated proteins in greater detail below.
Figure 4A represents a cluster of secreted proteins expressed
at high levels at the beginning of adipogenesis that decreased
during the process of differentiation despite some ﬂuctuations
on Days 6 or 9. For example, lactotransferrin, a member of the
transferrin family, an iron-binding glycoprotein, has recently
been shown to suppress adipogenesis.
22,23 Indeed, our results
showed a decrease in secreted lactotransferrin levels as preadi-
pocytes differentiate into mature adipocytes, consistent with
its proposed inhibitory role in adipogenesis. Another protein
whose levels decreased in the course of adipocyte differentia-
tion is the PDZ domain-containing protein, InaD-like protein
(INADL), thought to play a role in tight junctions. This protein
has never been described in the context of adipocyte biology.
Although lacking a conventional signal peptide, INADL has
been detected in serum.
24 The exact function of this protein
in adipocytes is currently unknown. Nevertheless, our study
illustrates the power of mass spectrometry to identify novel
adipocyte secreted proteins in an unbiased fashion. Another
interesting molecule exhibiting this pattern is a classic adipok-
ine, plasminogen activator inhibitor-1 (PAI-1), induced by
proinﬂammatory cytokines TNF-R in adipocytes and adipose
tissue.
25 Serum PAI-1 levels are positively correlated with tissue
insulin resistance and the risk for developing cardiovascular
diseases.
26 Consistent with a previous study, we observed that
secreted PAI-1 protein levels decreased during primary human
adipocyte differentiation in culture. Biglycan, a small leucine-
research articles Zhong et al.
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and muscle regeneration. In humans, biglycan is also involved
in osteogenesis.
27 We have previously shown that during mouse
adipogenesis, secreted biglycan levels dramatically increased
∼8 fold from day 0 to day 3, then decreased back to the baseline
levels by the end of differentiation.
12 In contrast, secreted
human biglycan level in the secretome decreased at the
initiation of adipocyte differentiation, without exhibiting an
early phase induction, indicating subtle differences between
primary human adipocytes and the 3T3-L1 mouse adipocyte
systems.
Figure 4B represents a cluster of proteins whose levels
increased shortly after the initiation of differentiation (Day 0),
reaching their peak levels in the middle of the process (Day 6
or 9), followed by a decrease at Day 12 where adipocytes
acquired their mature phenotype. We identiﬁed multiple
interesting proteins exhibiting this pattern. For example, cathe-
psin C, a cysteine proteinase belonging to the peptidase C1
family, activates a number of granule-associated serine pro-
teases with pro-inﬂammatory and immunological roles by
cleaving off their inhibitory N-terminal dipeptides.
28 Loss-of-
function mutations of cathepsin C in humans cause Papillon-
Lefevre syndrome, an autosomal recessive disorder character-
ized by palmoplantar keratosis and periodontitis.
29 Despite
lacking a classical signal peptide, cathepsin C is present in
human serum.
30 Indeed, this is the ﬁrst study to demonstrate
cathepsin C as part of the secretome during human adipogen-
esis, suggesting a potentially important role for this protease
in adipocyte differentiation. Dimethylarginine dimethylami-
nohydrolase 1, which is also observed in this cluster, regulates
Figure 1. Differentiation of human preadipocytes to mature adipocytes. (A) Representative bright ﬁeld images of subcutaneous fat
depot-derived preadipocytes (Day 0) and day-6, 9, 12 differentiated adipocytes. (B) Proteins in the conditioned media were resolved by
SDS-PAGE and visualized by silver staining.
Temporal Proﬁling of the Secretome research articles
Journal of Proteome Research • Vol. 9, No. 10, 2010 5231Figure 2. iTRAQ-based quantitative proteomics. In the course of differentiation from human preadipocytes to adipocytes, conditioned
media were harvested, desalted, and concentrated. The protein samples were subjected to reduction, alkylation, and tryptic digestion.
After labeling with iTRAQ labeling reagent, the resulting peptides were mixed and fractionated by strong cation exchange liquid
chromatography. Each fraction was analyzed by LC-MS/MS on an LTQ-Orbitrap Fourier transform mass spectrometer.
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nitric oxide synthase activity. Although generally considered
to be an intracellular protein, dimethylarginine dimethylami-
nohydrolase 1 is present in human cerebrospinal ﬂuid.
31 Our
data showing a reduction of dimethylarginine dimethylami-
nohydrolase 1 in mature primary human adipocytes is consis-
tent with the described role of nitric oxide in suppressing
mouse adipocyte differentiation.
32 Another newly identiﬁed
protein in this cluster is hemicentin 1. The human HMCN1 gene
encodes a 600-kDa protein containing 5635 amino acid residues
that belongs to the family of the extracellular matrix proteins,
ﬁbulins. Recent reports accumulated evidence that variations
in HMCN1 play a role in age-related macular degeneration.
33
Most recently, Kim and colleagues found an association of
diabetic nephropathy with HMCN1. Here, our data showed that
hemicentin 1 exhibited different expression patterns from other
ﬁbrilins - ﬁbrilin 1, 2, and 5 - identiﬁed in our studies and that
the secretion of this protein was increased from Day 0 until
Day 9 then decreased on Day 12, suggesting that hemicentin 1
may play a different role from other ﬁbrilins in adipocyte
differentiation.
Figure 4C represents the third and largest cluster of secreted
proteins whose protein levels consistently increased throughout
the entire process of differentiation. We have identiﬁed many
proteins belonging to this cluster. One such protein is glypican-
1, a GPI-anchored cell surface heparan sulfate proteoglycan that
is part of a larger family of glypicans. Many GPI-anchored
proteins are released into the extracellular milieu by the action
of phosphatidylinositol- speciﬁc phospholipase C (PI-PLC) that
cleave at the GPI anchor, likely accounting for glypican-1
presence in the human adipocyte secretome. A related member
of the same family, glypican-3, interacts with the glucose
transporter GLUT4 to facilitate glucose uptake into cells.
34
Thus, as with glypican-3, glypican-1 may play a similar role in
human adipocytes. Another interesting family of proteins in
this cluster is the tropomyosins. We have previously shown a
ﬂuctuation of the secretion of tropomyosins during mouse 3T3-
L1 adipocyte differentiation where secretion of tropomyosin
1, 3, and 4 was decreased from day 1 to day 2, increased on
day 3 or day 4 and then decreased again on day 5 and that the
level of tropomyosins on day 1 was higher than days 2-5.
However, we observed two different expression patterns of
tropomyosins during the course of adipocyte differentiation in
humans where the levels of tropomyosin 1 and 2 were continu-
ously increased from day 0 to day 12 and that the levels of
human tropomyosin 3 and 4 were increased from day 0 to day
Figure 3. MS/MS spectra of iTRAQ labeled peptides from representative differentially secreted proteins identiﬁed in this study. (A)
Adiponectin; (B) Lactotransferrin; (C) dimethylarginine dimethylaminohydrolase 1; and (D) Cathepsin B. (Insets) Reporter ions generated
during MS/MS that were used for quantitation.
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highlights the difference between primary human adipocyte
and the mouse 3T3-L1 adipocyte system. Another interesting
family of proteins in this cluster are collagens. Khan and
colleagues have previously shown that collagens I, IV and VI
are abundantly expressed in mature adipocytes and that
knockout of collagen VI in ob/ob mice improved metabolic
phenotype.
35 Their results also suggest that collagen VI affects
the ability of adipocytes to expand. Interestingly, our data also
show that the expression levels of collagen VI and other
collagens were increased during the course of the differentia-
tion of preadipocytes to adipocytes in humans. One newly
identiﬁed protein in this cluster is SPARC related modular
calcium binding protein 1 (SMOC1), a 51-kDa secreted glyco-
protein. SMOC1 contains ﬁve domains: two thyroglobulin-like
domains, one Kazal-type serine protease inhibitor domain and
two EF-hand calcium-binding domains. SMOC1 has 37%
homology to a well-known adipokine, SPARC/osteonectin, at
the amino acid level. SPARC has been associated with obesity
and secretion of SPARC by adipose tissue is increased by
insulin.
36 SMOC1 may also play a similar role in human
adipogenesis. Another newly identiﬁed protein in this cluster
is dermcidin. Dermcidin was originally identiﬁed as a broad-
spectrum antibiotic peptide secreted by sweat glands.
37 The
110 amino acid long protein dermcidin can be proteolytically
processed to generate the C-terminal peptide and N-terminal
peptide. As a cancer cell survival factor, the N-terminal peptide
(also called proteolysis-inducing-factor or Y-P30 peptide)
confers a survival advantage in breast and prostate cancer cells
against oxidative stress and hypoxia.
38-40 The C-terminal
peptide DCD-1 L containing 47 amino acid residues has
antibiotic activities and can further be proteolytically processed
to shorter fragments by cathepsin D after secretion, which also
have antibiotic activities.
41 Interestingly, our proteomics data
showed that dermcidin and cathepsin D exhibited similar
expression pattern during the course of differentiation, sug-
gesting that dermcidin may play an important role in adipocyte
differentiation.
Functional Analysis of Identiﬁed Proteins. We carried out
a literature-based functional analysis by searching the identiﬁed
proteins against the manually curated Human Protein Refer-
ence Database (HPRD)
42 and Human Proteinpedia.
43,44 HPRD
uses multiple bioinformatic programs to predict the existence
of a signal peptide located at the N-termini of proteins. Of the
420 proteins, 164 were predicted to have a signal peptide. HPRD
and Human Proteinpedia also provide experimentally veriﬁed
information concerning the cellular and subcellular localization
of proteins. Although many adipokines have already been
identiﬁed over the years,
11,12,14-16,45 we were still able to
discover a number of novel adipokines, thus highlighting the
power of mass spectrometry to complement other existing
approaches to more comprehensively enumerate the secretome
of adipocytes. During the preparation of this manuscript, Kim
and colleagues published a label-free shotgun proteomics
strategy to compare proteins secreted by the stromal vascular
cells versus those secreted by differentiated human adipo-
cytes.
46 To the best of our knowledge, 107 proteins that we have
identiﬁed in the human adipocyte secretome have still not been
previously described by other studies including the study by
Kim et al. (Supplementary Table 2, Supporting Information).
A subset of these novel proteins is listed in Table 1.
Antibody Arrays for Temporal Analysis of the Adipocytes
Secretome. We have previously used Western blot analysis to
validate temporal changes of a limited set of proteins identiﬁed
from the secretome of mouse adipocytes. However, several
drawbacks are associated with this approach. First, Western
blot-based validation strategy is greatly limited by the avail-
ability of existing antibodies that can speciﬁcally recognize their
target proteins on immunoblots. In general, good antibodies,
whether they are from a commercial or noncommercial source,
exist only for well-described proteins. Many of the secretory
proteins we have identiﬁed in the present study are not in this
category of such well-studied proteins. Second, the enhanced
chemiluminescence detection method often used in conjunc-
tion with Western blot analysis is not strictly quantitative. Third,
it is time-consuming, manually demanding and cost prohibitive
to carry out Western blot analysis for a large number of
candidates. Due to these limitations, we decided to use a
different antibody array platform to quantify the expression
levels of adipokines during adipogenesis.
Antibody arrays have been used to quantify the secreted
cytokine levels in many biological contexts.
47-49 We chose a
commercially available adipokine antibody array to validate
some of our ﬁndings. An advantage of using these arrays is that
Figure 4. Dynamic expression patterns of proteins identiﬁed from
the secretome of adipocytes during the course of differentiation.
(A-C) Examples of proteins belonging to these distinct patterns.
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us to proﬁle proteins of low abundance (especially cytokines
and chemokines) that might not easily be identiﬁed by mass
spectrometry. These commercial arrays contain speciﬁc anti-
bodies directed against 182 proteins (spotted in triplicate)
known to be secreted by adipocytes/adipose tissue and four
replicate arrays are spotted on one glass slide. Of these
antibodies, 19 were directed against proteins we identiﬁed in
this study. The proteins from the conditioned media on Days
0, 6, 9, and 12 were biotinylated and incubated with antibody
arrays. The bound proteins were detected by ﬂuorescent dye-
conjugated streptavidin. The signals visualized from the four
time points were normalized and quantiﬁed based on a set of
common controls spotted across the arrays. Although the arrays
were designed to detect picogram levels of proteins, 14 adi-
pokines were not detected in the secretome at any of the four
time points (Supplementary Table 3, Supporting Information).
Further, the signals for almost half of the spots on the arrays
were zero, suggesting that the concentrations of many adipok-
ines in the cultured media were still below the detection limit
of the antibody arrays or that there was no speciﬁc binding to
those antibodies. Among the 19 proteins common to the arrays
and mass spectrometric analysis, the expression patterns of
nine proteinssadiponectin, adipsin, apolipoprotein E, glu-
tathione peroxidase 3, clusterin, galectin-1, cystatin C, os-
teonectin and matrix metalloproteinase 2sshowed similar
trends as that obtained by mass spectrometry. As shown in
Figure 5, relative expression of six of nine proteins measured
by antibody arrays and mass spectrometry were compared. Five
proteinsspentraxin 3, pigment epithelium derived factor, S100
calcium binding protein A10, tissue inhibitor of metallopro-
teinase 1 and 2swere below the detection limits of the antibody
arrays. Five proteins, FABP4, M-CSF, PDGF-D, Thrombospon-
din 1 and 2, showed expression patterns that were different
from those observed by mass spectrometry. Other than these
proteins, we were also able to quantify the secreted levels of
many other adipokines not detected by our mass spectrometry
analysis. Importantly, the secreted levels of many adipokines
also differ during the course of adipocyte differentiation.
Overall, it is clear that the unique strength of mass spectrometry
and antibody arrays are complementary and can provide
insights into the dynamic changes in the adipocyte secretome
during differentiation.
Conclusions
The mouse 3T3-L1 adipocyte culture system has been widely
used as a model to study molecular mechanisms of adipogen-
esis. A number of groups have used proteomic methods to
analyze the secretome during the differentiation of preadipo-
cytes into mature 3T3-L1 adipocytes. Only very recently have
studies been conducted to analyze the secretome of human
adipocytes. These studies that mainly used 2D gels focused
solely on a simple comparison of two cellular statespreadi-
pocytes and differentiated mature adipocytessthus precluding
a dynamic snapshot of the entire differentiation process. The
inherent limitations of 2D gels makes it likely that the entire
complement of secreted proteins in adipocytes has not been
fully enumerated.
50 To overcome these limitations, we used
the iTRAQ methodology to monitor and quantify the levels of
proteins in the secretome of primary human adipocytes at
different stages of differentiation. Our study not only identiﬁed
and conﬁrmed multiple secreted proteins known to be ex-
pressed by human adipocytes, but also revealed several novel
adipokines. Our analysis also uncovered three major dynamic
expression patterns of adipokines during the differentiation
process. Further, we used antibody arrays to complement,
validate and extend the temporal analysis of human adipocyte
secretome. In summary, this is the ﬁrst large-scale quantitative
proteomic study that combines two orthogonal and comple-
mentary platforms to enable a more comprehensive under-
standing of human adipogenesis.
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Table 1. Subset of Novel Proteins Identiﬁed in the Secretome during Human Adipogenesis
gene symbol GI accession protein
abundance ratio
day 0/day 12 day 6/day 12 day 9/day 12
DCN 19743846 Decorin 1.4 ( 0.4 1.4 ( 0.4 1.6 ( 0.3
SPOCK1 4759164 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan 1 1.0 ( 0.3 1.6 ( 0.2 1.3 ( 0.1
HMCN1 118572606 Hemicentin 1 0.8 ( 0.4 0.7 ( 0.3 1.7 ( 0.9
APOD 4502163 Apolipoprotein D 0.6 ( 0.4 1.6 ( 0.5 1.7 ( 0.04
COL5A3 110735435 Collagen, type V, alpha 3 0.6 ( NA 0.2 ( 0.2 0.8 ( 0.3
CTHRC1 19923989 Collagen triple helix repeat containing 1 0.6 ( 0.2 1.0 ( 0.3 1.4 ( 0.04
LAMA2 119466532 Laminin alpha 2 subunit 0.5 ( 0.1 1.3 ( 0.2 1.4 ( 0.3
CRLF1 4758062 Cytokine receptor-like factor 1 0.5 ( NA 1.8 ( NA 1.7 ( NA
PRSS1 4506145 Protease, serine, 1 0.5 ( NA 0.5 ( NA 0.5 ( NA
MASP1 21264359 Mannan-binding lectin serine protease 1 0.4 ( NA 1.2 ( NA 1.1 ( NA
FBN2 66346695 Fibrillin 2 0.4 ( 0.1 1.0 ( 0.02 1.1 ( 0.1
SMOC1 11545873 SPARC related modular calcium-binding protein 1 0.4 ( NA 0.5 ( NA 0.7 ( NA
DCD 16751921 Dermcidin 0.3 ( NA 0.8 ( NA 1.5 ( NA
HDGF 4758516 Hepatoma-derived growth factor 0.3 ( NA 0.8 ( NA 1.9 ( NA
GPC1 4504081 Glypican 1 0.3 ( NA 0.7 ( NA 1.1 ( NA
TXNRD1 33519426 Thioredoxin reductase 1 0.2 ( 0.2 0.9 ( 0.2 1.8 ( 0.8
ITIH2 70778918 Interalpha globulin inhibitor H2 polypeptide 0.2 ( 0.1 0.7 ( 0.1 2.0 ( 0.1
ANPEP 4502095 Membrane alanine aminopeptidase 0.2 ( 0.1 0.6 ( 0.03 1.1 ( 0.03
LGALS3 115430223 Galectin 3 0.2 ( 0.1 0.5 ( 0.1 1.2 ( 0.3
ITIH4 31542984 Interalpha (globulin) inhibitor H4 0.2 ( NA 0.3 ( NA 1.3 ( NA
AHSG 4502005 Alpha-2-HS-glycoprotein 0.1 ( 0.1 0.3 ( 0.1 1.7 ( 0.3
PCOLCE2 7019483 Procollagen C-endopeptidase enhancer 2 0.2 ( NA 0.6 ( NA 1.3 ( NA
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